2'-deoxy-2'-methylthioadenosine | 30545-89-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2'-deoxy-2'-methylthioadenosine
• 英文别名: 2'-S'-Methyl-2'-thioadenosin；S-methyl-2'-thio-adenosine；S-methylthioadenosine；(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-methylsulfanyloxolan-3-ol
• CAS: 30545-89-2
• 化学式: C₁₁H₁₅N₅O₃S
• 分子量: 297.338
• InChiKey: KXLYDMYMNDAXPA-IOSLPCCCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  145
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2'-deoxy-2'-methylthioadenosine 在 吡啶 、 偶氮二异丁腈 、 三正丁基氢锡 作用下， 以 甲苯 为溶剂， 反应 2.5h， 生成 5'-O-(tert-butyldimethylsilyl)-2'-deoxyadenosine
  参考文献：
  名称：

  Nucleic Acid Related Compounds. 91. Biomimetic Reactions Are in Harmony with Loss of 2‘-Substituents as Free Radicals (Not Anions) during Mechanism-Based Inactivation of Ribonucleotide Reductases. Differential Interactions of Azide, Halogen, and Alkylthio Groups with Tributylstannane and Triphenylsilane¹

  摘要：

  The initial step in the mechanism-based inactivation of ribonucleotide reductases by 2'-chloro-2'-deoxynucleotides is abstraction of H3' by a proximal free radical on the enzyme. The C3' radical is postulated to undergo spontaneous loss of chloride, and the resulting cationic radical loses a proton to give a 3'-keto intermediate. Successive beta-eliminations produce a Michael acceptor which causes inactivation. This hypothesis would predict rapid loss of mesylate or tosylate anions from C2', but sluggish loss of azide or thiomethoxide. in contrast, loss of azido and methylthio radicals from C2' should occur readily whereas homolysis to give (methyl or tolylsulfonyl)oxy and fluoro radicals should be energetically prohibitive. Protected 3'-O-(phenoxythiocarbonyl)-2'-substitute nucleosides were treated with tributylstannane/AIBN or triphenylsilane/dibenzoyl peroxide in refluxing toluene. The 2'-O-(mesyl and tosyl) and 2'-fluoro compounds underwent direct radical-mediated hydrogenolysis of the thionocarbonate group to give 3'-deoxy-2'-substituted products, whereas 2'-(azido, bromo, chloro, iodo, and methylthio)-3'-thionocarbonates gave 2',3'-didehydro-2',3'-dideoxy derivatives via loss of 2'-substituents from an incipient C3' radical. These results are in harmony with loss of radicals, but not anions, from C2'. The well-known radical-mediated hydrogenolytic cleavage of halogen and methylthio (slow) groups from C2' of the S'-hydroxy (unprotected) precursors and reduction of 2'-azides to amines occurred with tributylstannane/AIBN. Triphenylsilane/dibenzoyl peroxide gave parallel (but slower) hydrogenolysis with the 2'-(iodo, bromo, and methylthio) compounds, but cleavage of the 2'-chloro group was very slow and no reduction of 2'-azides to amines was detected. Rather, the latter system effected slow hydrogenolytic removal of the 2'-azido group. Thus, chemoselective differentiation of certain functional groups is possible with triphenylsilane and tributylstannane. Reduction of azides to amines with tributylstannane is known, but hydrogenolytic deazidation (slow) with triphenylsilane in the absence of amine formation appears to be novel.

  DOI：

  10.1021/ja962117m
• 作为产物：
  描述：

  2'-O-triflyl-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-ara-adenosine 在 四丁基氟化铵 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.75h， 生成 2'-deoxy-2'-methylthioadenosine
  参考文献：
  名称：

  2'-脱氧-2'-甲硫基嘧啶和-嘌呤核苷的合成及构象性质：潜在的反义应用†

  摘要：

  实现了2'-脱氧-2'-甲基硫尿苷类似物5，-5-甲基尿苷6，-胞嘧啶15，-5-甲基胞苷16，-腺苷27和-鸟苷34的方便且较短的合成。核糖核苷（5-甲基U，U，A，G）为相应的2'-取代的核苷的成功转换涉及亲核置换（S Ñ适当的离去基团在由甲硫醇2'-位置，软亲核试剂的2）。N 1，N 1，N 3，N 3的存在下2,2'-脱水尿苷与甲硫醇的反应在N，N-二甲基甲酰胺中的-四甲基胍-丁以75％的收率得到5。描述了通过类似途径制备6。酰化的5和6转化为其三唑衍生物，通过氨解反应可分别获得15和16的高收率。类似地，在存在1,8-二氮杂双环[5.4.0]十一烷基-7-烯的情况下，四异丙基二硅氧烷基（TIPS）保护的2' - O-芳基腺苷和-鸟苷与甲硫醇在-25°下反应，然后解封TIPS保护组的成员提供了27和34， 分别。所述CONFOR-mational灵活性在核苷糖部分的（N / S平衡

  DOI：

  10.1002/jhet.5570300518

文献信息

• Combination therapies for treating methylthioadenosine phosphorylase deficient cells
  申请人：——

  公开号：US20040043959A1

  公开（公告）日：2004-03-04

  The present invention is directed to combination therapies for treating cell proliferative disorders associated with methylthioadenosine phosphorylase (MTAP) deficient cells in a mammal. The combination therapies selectively kill MTAP-deficient cells by administering an inhibitor of de novo inosinate synthesis and administering an anti-toxicity agent, wherein the inhibitors of de novo inosinate synthesis are inhibitors of glycinamide ribonucleotide formyltransferase (“GARFT”) and/or aminoinidazolecarboximide ribonucleotide formyltransferase (“AICARFT”), and the anti-toxicity agent is an MTAP substrate (e.g. methylthioadenosine or “MTA”), a precursor of MTA, an analog of an MTA precursor or a prodrug of an MTAP substrate.

  本发明涉及用于治疗哺乳动物中与甲基硫腺苷磷酸化酶（MTAP）缺乏细胞相关的细胞增殖性疾病的联合疗法。该联合疗法通过给予新生核苷酸合成抑制剂和给予抗毒性剂，选择性地杀死MTAP缺乏细胞，其中，新生核苷酸合成抑制剂是甘氨酰核苷酸甲酰转移酶（“GARFT”）和/或氨基咪唑羧酰核苷酸甲酰转移酶（“AICARFT”）的抑制剂，抗毒性剂是MTAP底物（例如，甲基硫腺苷或“MTA”），MTA的前体，MTA前体的类似物或MTAP底物的前药。
• COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS
  申请人：PFIZER INC.

  公开号：EP1482977A1

  公开（公告）日：2004-12-08
• [EN] COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS<br/>[FR] POLYTHERAPIES POUR TRAITER DES CELLULES A DEFICIENCE EN METHYLTHIOADENOSINE PHOSPHORYLASE
  申请人：PFIZER

  公开号：WO2003074083A1

  公开（公告）日：2003-09-12

  The present invention is directed to combination therapies fro treating cell proliferative disorders associated with methylthioadenosine phosphorylase (MTAP) deficient cells in a mammal. The combination therapies selectively kill MTAP-deficient cells by administering an ihibitor of de novo inosinate synthesis and administering an anti-toxicity agent, wherein the inhibitors of de novo inosinate synthesis are inhibitors of glycinamide ribonucleotide formyltransferase ('GARFT') and/or aminoinidazolecarboximide ribonucleotide formyltransferase ('AICARFT'), and the anti-toxicity agent is an MTAP substrate (e.g. methylthioadenosine or 'MTA'), a precursor of MTA, an analog of an MTA precursor or a prodrug of an MTAP substrate.